Veeva CRM - sync readyTarget month October 2026

DYNAMIC CALLING - HER2+ mBC REP TARGET LIST

Physicians are prioritized by HER2+ mBC volume and near-term maintenance opportunity, with added signals for recent induction starts, brain metastases, and prior Tukysa use. The prioritization also considers access, practice affiliation, clinical influence, referral patterns, and first-line treatment mix to identify the highest-potential targets for this period's list.

3004
Targets in view
994
High-priority HCPs
0
Feedback recorded
3
Territories shown
Priority
View
HCOReason for prioritizationRep feedback
High
Jordan Blake
NPI 1902384710
Northeast
02138
High-volume HER2+ mBC prescriber; strong fit for Tukysa
High
Jordan Blake
NPI 1774920185
Northeast
02114
KOL in HER2+ breast cancer; speaker bureau candidate
Medium
Jordan Blake
NPI 1638201947
Northeast
02139
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Jordan Blake
NPI 1583920174
Northeast
02116
High unmet need; low share of voice versus competitor HER2-directed therapies
High
Jordan Blake
NPI 1290384756
Northeast
02108
Recent formulary win; reinforce with clinical data
Medium
Jordan Blake
NPI 1467820391
Northeast
02143
Requested more data on the combination regimen
Low
Jordan Blake
NPI 1839204756
Northeast
02140
Regional influencer whose referral network drives peer prescribing
High
Jordan Blake
NPI 1920384756
Northeast
02142
New to territory; introductory call and account profiling needed
Medium
Jordan Blake
NPI 1029384756
Northeast
02138
Lapsed prescriber with strong third-line and later patient volume
Low
Jordan Blake
NPI 1746382910
Northeast
01960
Positive feedback from last MSL visit; open to discussing National Comprehensive Cancer Network guidelines
High
Priya Anand
NPI 1385920471
Midwest
60611
Site for the HER2CLIMB clinical trial; opportunity to convert trial experience into commercial use
High
Priya Anand
NPI 1573820194
Midwest
60614
Declining new patient starts; retention call needed
Medium
Priya Anand
NPI 1204837561
Midwest
60622
High-decile prescriber with low or no recent calls (coverage gap)
Low
Priya Anand
NPI 1739284650
Midwest
60647
Payer or reimbursement barrier limiting starts; offer Pfizer access support
High
Priya Anand
NPI 1830294756
Midwest
60611
Community oncologist with high patient throughput per rep visit
Medium
Priya Anand
NPI 1029475830
Midwest
60603
Attended a recent congress session on Tukysa data; timely follow-up window
Low
Priya Anand
NPI 1746293850
Midwest
60605
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
High
Priya Anand
NPI 1928374650
Midwest
60611
Asked about patient support and copay program details
Medium
Priya Anand
NPI 1837465920
Midwest
60661
Engaging with Tukysa digital content; warm lead for a live call
Low
Priya Anand
NPI 1029384712
Midwest
60608
Strong patient panel but historically low engagement; test-and-learn target
High
Marcus Chen
NPI 1483920175
West
94108
High-volume HER2+ mBC prescriber; strong fit for Tukysa
High
Marcus Chen
NPI 1574839201
West
94115
KOL in HER2+ breast cancer; speaker bureau candidate
Medium
Marcus Chen
NPI 1029475831
West
94123
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Marcus Chen
NPI 1738294650
West
94110
Community oncologist with high patient throughput per rep visit
High
Marcus Chen
NPI 1928374561
West
94143
Regional influencer whose referral network drives peer prescribing
Medium
Marcus Chen
NPI 1837465021
West
94123
Engaging with Tukysa digital content; warm lead for a live call
Low
Marcus Chen
NPI 1029384621
West
94118
Requested more data on the combination regimen
High
Marcus Chen
NPI 1746392851
West
94108
Site for the HER2CLIMB clinical trial; opportunity to convert trial experience into commercial use
Medium
Marcus Chen
NPI 1928475603
West
94103
Attended a recent congress session on Tukysa data; timely follow-up window
Low
Marcus Chen
NPI 1837294056
West
94118
Payer or reimbursement barrier limiting starts; offer Pfizer access support
High
Jordan Blake
NPI 1000000000
Northeast
02118
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Low
Jordan Blake
NPI 1000007919
Northeast
02130
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Medium
Jordan Blake
NPI 1000015838
Northeast
02446
High-decile prescriber with low or no recent calls (coverage gap)
Low
Jordan Blake
NPI 1000023757
Northeast
01890
Engaging with Tukysa digital content; warm lead for a live call
Medium
Jordan Blake
NPI 1000031676
Northeast
01742
New to territory; introductory call and account profiling needed
High
Jordan Blake
NPI 1000039595
Northeast
02118
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Medium
Jordan Blake
NPI 1000047514
Northeast
02130
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Low
Jordan Blake
NPI 1000055433
Northeast
02446
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Medium
Jordan Blake
NPI 1000063352
Northeast
01890
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Jordan Blake
NPI 1000071271
Northeast
01742
High-decile prescriber with low or no recent calls (coverage gap)
High
Avery Morgan
NPI 1100000000
Northeast
02118
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Avery Morgan
NPI 1100007919
Northeast
02130
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Avery Morgan
NPI 1100015838
Northeast
02446
Engaging with Tukysa digital content; warm lead for a live call
Low
Avery Morgan
NPI 1100023757
Northeast
01890
New to territory; introductory call and account profiling needed
Medium
Avery Morgan
NPI 1100031676
Northeast
01742
Payer or reimbursement barrier limiting starts; offer Pfizer access support
High
Avery Morgan
NPI 1100039595
Northeast
02118
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Medium
Avery Morgan
NPI 1100047514
Northeast
02130
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Low
Avery Morgan
NPI 1100055433
Northeast
02446
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Medium
Avery Morgan
NPI 1100063352
Northeast
01890
High-decile prescriber with low or no recent calls (coverage gap)
Low
Avery Morgan
NPI 1100071271
Northeast
01742
Engaging with Tukysa digital content; warm lead for a live call
High
Avery Morgan
NPI 1100079190
Northeast
02118
New to territory; introductory call and account profiling needed
Low
Avery Morgan
NPI 1100087109
Northeast
02130
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Medium
Avery Morgan
NPI 1100095028
Northeast
02446
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Low
Avery Morgan
NPI 1100102947
Northeast
01890
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Medium
Avery Morgan
NPI 1100110866
Northeast
01742
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
High
Avery Morgan
NPI 1100118785
Northeast
02118
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Avery Morgan
NPI 1100126704
Northeast
02130
Engaging with Tukysa digital content; warm lead for a live call
Low
Avery Morgan
NPI 1100134623
Northeast
02446
New to territory; introductory call and account profiling needed
Medium
Avery Morgan
NPI 1100142542
Northeast
01890
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Low
Avery Morgan
NPI 1100150461
Northeast
01742
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
High
Priya Anand
NPI 1300000000
Midwest
60610
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Priya Anand
NPI 1300007919
Midwest
60618
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Priya Anand
NPI 1300015838
Midwest
55401
Engaging with Tukysa digital content; warm lead for a live call
Low
Priya Anand
NPI 1300023757
Midwest
48226
New to territory; introductory call and account profiling needed
Medium
Priya Anand
NPI 1300031676
Midwest
53202
Payer or reimbursement barrier limiting starts; offer Pfizer access support
High
Priya Anand
NPI 1300039595
Midwest
60610
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Medium
Priya Anand
NPI 1300047514
Midwest
60618
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Low
Priya Anand
NPI 1300055433
Midwest
55401
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Medium
Priya Anand
NPI 1300063352
Midwest
48226
High-decile prescriber with low or no recent calls (coverage gap)
Low
Priya Anand
NPI 1300071271
Midwest
53202
Engaging with Tukysa digital content; warm lead for a live call
High
Daniel Brooks
NPI 1400000000
Midwest
60610
High-decile prescriber with low or no recent calls (coverage gap)
Low
Daniel Brooks
NPI 1400007919
Midwest
60618
Engaging with Tukysa digital content; warm lead for a live call
Medium
Daniel Brooks
NPI 1400015838
Midwest
55401
New to territory; introductory call and account profiling needed
Low
Daniel Brooks
NPI 1400023757
Midwest
48226
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Medium
Daniel Brooks
NPI 1400031676
Midwest
53202
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
High
Daniel Brooks
NPI 1400039595
Midwest
60610
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Medium
Daniel Brooks
NPI 1400047514
Midwest
60618
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Daniel Brooks
NPI 1400055433
Midwest
55401
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Daniel Brooks
NPI 1400063352
Midwest
48226
Engaging with Tukysa digital content; warm lead for a live call
Low
Daniel Brooks
NPI 1400071271
Midwest
53202
New to territory; introductory call and account profiling needed
High
Daniel Brooks
NPI 1400079190
Midwest
60610
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Low
Daniel Brooks
NPI 1400087109
Midwest
60618
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Medium
Daniel Brooks
NPI 1400095028
Midwest
55401
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Low
Daniel Brooks
NPI 1400102947
Midwest
48226
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Medium
Daniel Brooks
NPI 1400110866
Midwest
53202
High-decile prescriber with low or no recent calls (coverage gap)
High
Daniel Brooks
NPI 1400118785
Midwest
60610
Engaging with Tukysa digital content; warm lead for a live call
Medium
Daniel Brooks
NPI 1400126704
Midwest
60618
New to territory; introductory call and account profiling needed
Low
Daniel Brooks
NPI 1400134623
Midwest
55401
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Medium
Daniel Brooks
NPI 1400142542
Midwest
48226
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Low
Daniel Brooks
NPI 1400150461
Midwest
53202
High-volume HER2+ mBC prescriber; strong fit for Tukysa
High
Marcus Chen
NPI 1600000000
West
94105
High-decile prescriber with low or no recent calls (coverage gap)
Low
Marcus Chen
NPI 1600007919
West
94117
Engaging with Tukysa digital content; warm lead for a live call
Medium
Marcus Chen
NPI 1600015838
West
97205
New to territory; introductory call and account profiling needed
Low
Marcus Chen
NPI 1600023757
West
98101
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Medium
Marcus Chen
NPI 1600031676
West
85004
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
High
Marcus Chen
NPI 1600039595
West
94105
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Medium
Marcus Chen
NPI 1600047514
West
94117
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Marcus Chen
NPI 1600055433
West
97205
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Marcus Chen
NPI 1600063352
West
98101
Engaging with Tukysa digital content; warm lead for a live call
Low
Marcus Chen
NPI 1600071271
West
85004
New to territory; introductory call and account profiling needed
High
Sofia Ramirez
NPI 1700000000
West
94105
Engaging with Tukysa digital content; warm lead for a live call
Low
Sofia Ramirez
NPI 1700007919
West
94117
New to territory; introductory call and account profiling needed
Medium
Sofia Ramirez
NPI 1700015838
West
97205
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Low
Sofia Ramirez
NPI 1700023757
West
98101
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Medium
Sofia Ramirez
NPI 1700031676
West
85004
High-volume HER2+ mBC prescriber; strong fit for Tukysa
High
Sofia Ramirez
NPI 1700039595
West
94105
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Medium
Sofia Ramirez
NPI 1700047514
West
94117
High-decile prescriber with low or no recent calls (coverage gap)
Low
Sofia Ramirez
NPI 1700055433
West
97205
Engaging with Tukysa digital content; warm lead for a live call
Medium
Sofia Ramirez
NPI 1700063352
West
98101
New to territory; introductory call and account profiling needed
Low
Sofia Ramirez
NPI 1700071271
West
85004
Payer or reimbursement barrier limiting starts; offer Pfizer access support
High
Sofia Ramirez
NPI 1700079190
West
94105
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Low
Sofia Ramirez
NPI 1700087109
West
94117
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Medium
Sofia Ramirez
NPI 1700095028
West
97205
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial
Low
Sofia Ramirez
NPI 1700102947
West
98101
High-decile prescriber with low or no recent calls (coverage gap)
Medium
Sofia Ramirez
NPI 1700110866
West
85004
Engaging with Tukysa digital content; warm lead for a live call
High
Sofia Ramirez
NPI 1700118785
West
94105
New to territory; introductory call and account profiling needed
Medium
Sofia Ramirez
NPI 1700126704
West
94117
Payer or reimbursement barrier limiting starts; offer Pfizer access support
Low
Sofia Ramirez
NPI 1700134623
West
97205
Recent competitor HER2-directed therapy use; needs a data-led differentiation discussion
Medium
Sofia Ramirez
NPI 1700142542
West
98101
High-volume HER2+ mBC prescriber; strong fit for Tukysa
Low
Sofia Ramirez
NPI 1700150461
West
85004
Growing brain metastases caseload; strong fit for brain efficacy data from the HER2CLIMB clinical trial